Platelet Inhibition With CANgrelor and Crushed TICagrelor in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: The CANTIC Study
Phase of Trial: Phase IV
Latest Information Update: 20 Dec 2017
At a glance
- Drugs Cangrelor (Primary)
- Indications Myocardial infarction
- Focus Pharmacodynamics
- Acronyms CANTIC
- 13 Dec 2017 Status changed from not yet recruiting to recruiting.
- 24 Oct 2017 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019.
- 24 Oct 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018.